Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAK Immune Cells in Hepatobiliary and Pancreatic Malignancies
NCT05240690Phase 1Unknown
- Start
- Feb 2022
- Primary completion
- Dec 2023
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MAK Immune Cells in hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA) and pancreatic cancer (PC). Primary endpoint: Progression-free Survival at 24 months. Status: unknown.
02
Drugs
MAK Immune Cells
03
Conditions
hepatocellular carcinoma (HCC)cholangiocarcinoma (CCA)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05240690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05240690.